	US 12,006,518 B2
	Engineered polymerases with reduced sequence-specific errors
Jendrik Hentschel, San Diego, CA (US); Tyler Lopez, Winchester, CA (US); Michael Klein, Encinitas, CA (US); Virginia Saade, San Diego, CA (US); Matthew Kellinger, San Diego, CA (US); and Mark Ambroso, Escondido, CA (US)
Assigned to ELEMENT BIOSCIENCES, INC., San Diego, CA (US)
Filed by Element Biosciences, Inc., San Diego, CA (US)
Filed on Jan. 27, 2023, as Appl. No. 18/160,951.
Claims priority of provisional application 63/311,939, filed on Feb. 18, 2022.
Claims priority of provisional application 63/343,036, filed on May 17, 2022.
Claims priority of provisional application 63/479,490, filed on Jan. 11, 2023.
Prior Publication US 2023/0265401 A1, Aug. 24, 2023
Int. Cl. C12N 9/12 (2006.01); C12Q 1/6869 (2018.01)

CPC C12N 9/1252 (2013.01) [C12Q 1/6869 (2013.01); C12Y 207/07007 (2013.01)]

21 Claims

1. A composition comprising: a plurality of engineered polymerases comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 1316, and a plurality of modified nucleotides comprising a removable chain terminating moiety at the 3′ carbon position of the sugar group, wherein the plurality of engineered polymerases comprises amino acid substitutions Asp168Ala and Glu170Ala relative to SEQ ID NO:1316.